ChosenMed Announces Completion of Series C2 Financing to Advance Cancer Early Detection and Drug CRO Platforms

Recently, Qiuzhen Medical Technology (Beijing) Co., Ltd. (hereinafter referred to as “Qiuzhen Medical”) announced the completion of its C2 financing round, raising hundreds of millions of RMB. The round was led by Yijing Capital, with participation from Hangzhou Linzhuo Industrial Fund Co., Ltd. (hereinafter referred to as “Linzhuo Industrial Fund”) and other investors. The proceeds will be used to develop its proprietary pipeline of characteristic tumor early-screening products, construct R&D facilities, and optimize its drug CRO service platform.

As“Little Giant” Enterprises Specializing in Refinement, Innovation, and Uniqueness; Postdoctoral Research Workstations; Intellectual Property Demonstration Units; Scientific and Technological R&D Institutions; National High-Tech Enterprises, Qiuzhen Medical boasts an internationally top-tier management team. Leveraging its forward-looking vision, sustained R&D and innovation capabilities, unique market positioning, and high-quality products and services, the company has established multiple standardized oncology NGS medical testing laboratories, R&D centers, and production bases across China, and has successively partnered with more than 500 leading hospitals domestically andDozens ofBy partnering with new drug R&D enterprises, it quickly emerged as a dark horse in the oncology precision medicine industry.

It is worth noting that Qiuzhen Medical’s fundraising pace is also impressive within the industry, having successfully completed two consecutive rounds of financing in the second half of this year alone, which fully demonstrates the company’s comprehensive competitiveness and investment value.

As a leader in integrated solutions for precision oncology diagnosis and treatment, Qiuzhen Medical fully leverages the advantages of its NGS platform and multiple core patented technologies, particularlyPowerful Genomic Data Analysis CapabilitiesLeveraging the "China Cancer Gene Atlas Project" and the "Big Data Platform for Precision Oncology," we are deeply committed to the field of precision oncology, with business activities spanning cancer early screening, companion diagnostics, dynamic monitoring, prognostic assessment, and pharmaceutical CRO services.

The company has developedOver 20 varietiesFor Different Cancer TypesChosen SeriesCompanion diagnostic products for tumors: Clinical registration has been initiated for companion diagnostic products targeting lung cancer and gastrointestinal tumors.

As competition in the tumor NGS-based companion diagnostics market intensifies, expanding into more application scenarios and seeking new growth points have become wise choices for companies. In recent years, the tumor genetic testing industry has shown two major trends: one is to expand forward by laying out early screening products, and the other is to extend backward by developing MRD (Minimal Residual Disease) recurrence monitoring services. Early screening and MRD are also the focus areas where Qiuzhen Medical is making efforts.

In the highly watched field of tumor MRD, Qiuzhen Medical has developedChosenOne®MRDThe test product effectively filters out clonal hematopoiesis and reduces system noise by leveraging proprietary dual-end UMI tags, a triple-layer neural network denoising model, and a large-scale background noise database derived from tens of thousands of individuals. It enables postoperative tracking of personalized ctDNA mutation profiles in patients, facilitating accurate determination of MRD status and precise quantification of ctDNA.

Furthermore, since its inception, Qiuzhen Medical has been committed to establishing a platform for early cancer detection technologies and developing various products for early cancer screening, leveraging the proprietary innovations of its Chief Scientist, Professor Li Wei.“Methylation Canyon”Concept (Nature Genetics 2014): Detecting methylation valley biomarkers through proprietary self-developed algorithms, and applying methylation valley detection technology to cancer early screening products.

Qiuzhen Medical LaunchesThe First NGS Panel-Based Early Screening Product Utilizing Methylation Canyons, covering 150 characteristic loci, it can be used for screening pan-gastrointestinal tumors and tissue origin tracing, with sensitivity, specificity and other indicators superior to similar products.

Meanwhile, in response to market demand, Qiuzhen Medical has developedThe First Early Screening Product Based on MS-PCR Technology—Chosen Early Series, designed for the detection of liver cancer and other single cancer types in populations. This product boasts advantages such as high sensitivity, excellent specificity, and ease of adoption. Its performance metrics surpass those of the benchmark product that has received FDA Breakthrough Device designation, making it currentlyOne of the products best suited to clinical needs and most promising for commercial implementation and large-scale adoption, the related products have been granted multiple national invention patents.

Qiuzhen Medical has obtained 73 patents and 62 software copyrights, and published over 300 SCI-indexed articles.

“We have completed the construction of our R&D base for early cancer screening. Following this round of financing, we will gradually enhance our multi-omics platform, recruit professional talent specializing in early cancer screening, comprehensively layout our pipeline of early screening products, and advance R&D, regulatory submissions, and clinical services,” stated Dr. Zhou Qiming, Founder and President of Qiuzhen Medical.

Currently, based onZhongguancun National Innovation Demonstration Zone’s High-End and Advanced Industry Collaborative Innovation Platform—Big Data Platform for Precision Oncology; Beijing Municipal Science & Technology Commission Achievement Transformation Project—Medical AI Technology Transfer Service Platform, Qiuzhen Medical has undertaken multiple scientific research projects on big data and artificial intelligence platforms.

“For example, we participated in the national project ‘China Cancer Gene Atlas Program’ and a multi-center collaborative research project on TMB in NSCLC. We have also established partnerships with more than 500 top-tier hospitals across China, providing patients with precise tumor genetic testing services. This has not only laid a solid foundation for our basic research and the translation of applied achievements in tumor detection products, but also created significant advantages for the development of our company’s drug CRO service platform,” said Dr. Zhou Qiming.

During the clinical research phase,Addressing the Pain Point of Difficult Patient Recruitment for Pharmaceutical Companies(Data show that the probability of clinical trials gaining FDA approval is approximately 7%, and about one-third of Phase III clinical studies are terminated due to difficulties in patient recruitment. Data from IQVIA indicate that 37% of clinical trial sites experience insufficient patient enrollment.), Qiuzhen Medical leverages its platform advantages to establish biobanks (with organoid banks planned for the future), clinical databases, and multi-omics databases, thereby enhancing the efficiency of new drug development, providing support for sourcing rare samples, and facilitating Phase III clinical trials.

During the preclinical drug screening phase, Qiuzhen Medical assists in drug development.HotSpot3D: A Computational System for Candidate Drug Target Discovery(Nature Genetics 2016; Bioinformatics 2020), which can assist in drug development by identifying novel druggable cancer mutation sites. This computational system has supported domestic and internationalOver 110 research projects related to drug target discovery. Its online calculation system has now completed data from3,000+ Projects Across 62 Countries/Regions, and will help facilitate the research and development of more innovative drugs in the future.

HotSpot3D Druggable Site Discovery Computational System

Currently, the company has established strategic partnerships with dozens of domestic and international pharmaceutical companies and CROs, including Merck, AstraZeneca, Bayer, Lepu Medical, and Ping An Good Doctor. It provides “one-stop” solutions for biomarker discovery and validation, precision patient recruitment, new drug clinical trials, development and registration of companion diagnostic kits, and product performance optimization.

Whether in China or abroad, medical informatics analysis and artificial intelligence (AI) present higher technical barriers than wet-lab experiments, having become core competitive elements in tumor next-generation sequencing (NGS). Meanwhile, the value of multi-omics testing in the precision medicine industry is being gradually recognized and acknowledged.

Qiuzhen Medical’s World-Class Bioinformatics Innovation Capabilities: Early Publication, Multi-Omics, Multi-Level Analysis, and Ultra-High Citation Rates

Dr. Zhou Qiming stated, “In the future, precision oncology will inevitably advance more deeply in the direction of ‘multi-omics + AI,’ continuously expanding in both breadth and depth. In the field of early cancer screening, AI combined with accurate mutation detection can enable traceability, addressing the challenges of early screening and diagnosis of tumors. In the realm of new drug development, it can facilitate the discovery of novel biomarkers, thereby accelerating the R&D process of innovative drugs.”

Exclusively Possesses FDA-Approved Core Software for Bioinformatics Analysis

Qiuzhen Medical is one of the earliest companies in China to establishMulti-Omics Intelligent Platform(ChosenMIP) enterprises will further optimize early cancer screening products and accelerate the R&D of innovative drugs in China through this platform. Qiuzhen Medical will uphold its corporate mission of “Exploring Technological Innovation, Striving for Medical Excellence,” deepen its expertise in the field of precision oncology, lead the industry with innovation, and benefit the public with technology.

Jiang Min, Chairman of Linzhuo Industrial FundIt stated: “The 14th Five-Year Plan has clearly identified ‘genetics and biotechnology’ as one of the key frontier areas for scientific and technological breakthroughs and as a strategic emerging industry. The state encourages enterprises to actively participate in international competition, thereby enhancing the global influence of China’s medical services and the international competitiveness of its industries. Qiuzhen Medical possesses strong capabilities in technology R&D, bioinformatics analysis, and intelligent algorithm development, and will continue to develop more products for early cancer screening. Linzhuo Industrial Fund will provide comprehensive and sustained support to Qiuzhen Medical across multiple dimensions, including resource introduction, capital investment, and management improvement, jointly driving innovation in clinical cancer treatment in China.”

Dr. Qiming ZhouHe stated, “We extend our gratitude to the investors for their support and recognition. This round of financing will enable us to conduct large-scale tumor multi-omics cohort studies and further deepen our collaboration with innovative oncology pharmaceutical companies in the co-development of new drugs. We will also collaborate with industry expert societies to draft relevant expert consensus statements and industry standards, thereby introducing more high-quality products and services for precision oncology diagnosis and treatment into clinical practice, ultimately benefiting a broad population of cancer patients.”

Hangzhou Linzhuo Industrial Fund Co., Ltd. (hereinafter referred to as “Linzhuo Industrial Fund”) is a fund established under the guidance of the Linping District Government of Hangzhou and operated in accordance with market-oriented principles. Adhering to the investment principles of “government guidance, market-based operation, classified management, scientific decision-making, controllable risks, and rolling development,” the fund is functionally positioned to “support leading industries, facilitate investment promotion, attract and cultivate listed companies, and foster industrial ecosystems.” It supports projects in Linping District’s key sectors, including high-end equipment manufacturing, life and health, fashion industry, and industrial internet, guiding financial capital to better support the real economy, technological and industrial innovation, thereby enhancing the level of innovation and entrepreneurship and promoting industrial transformation and upgrading in Linping District.

Qiuzhen Medical is a national high-tech enterprise dedicated to the field of precision oncology. Built on next-generation sequencing (NGS) and advanced data mining technologies, and leveraging initiatives such as the “China Cancer Gene Atlas Project” and the “Big Data Platform for Precision Oncology,” the company deeply integrates genetic testing with artificial intelligence. It is committed to the development and intelligent iterative upgrading of diagnostic products in the field of liquid biopsy for cancer, with business coverage spanning multiple application scenarios including early cancer screening, companion diagnostics, dynamic monitoring, and prognostic assessment. Meanwhile, Qiuzhen Medical continuously explores and identifies baseline and specific biomarkers of cancer in the Chinese population, thereby facilitating the research and development of anti-tumor drugs. The company has successfully obtained certification from the College of American Pathologists (CAP) and achieved perfect scores in nearly 100 external quality assessment programs organized by authoritative domestic and international institutions, including the National Center for Clinical Laboratories (NCCL), the European Molecular Genetics Quality Network (EMQN), and CAP. Its medical laboratory quality management standards have attained recognition at the highest international level.